Displaying archives for 2017 May:

FDA Approves KEYTRUDA as First-Line Combination Therapy, Irrespective of PD-L1 Expression

Posted by ALCF Staff on May 10th, 2017 |

Congratulations, Merck, for the approval of KEYTRUDA® in first-line combo therapy irrespective of PD-1 expression. The improved responses seen with KEYTRUDA® plus… Read More